NovaBay Pharmaceuticals Launches NovaWipes Eyelid Wipes on Amazon.com
December 02 2019 - 6:50AM
Business Wire
Dry wipes are specifically designed for
applying Avenova® to treat dry eye and blepharitis
NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announces
the launch of NovaWipes, a dry, soft, hypoallergenic and absorbable
wipe for use in applying Avenova®, on Amazon.com. Avenova Direct,
NovaBay’s prescription-strength lid and lash spray, is also
available on Amazon.com without a prescription.
“Our soft and absorbent NovaWipes are perfect for applying
Avenova to eyelids irritated by the symptoms of dry eye and
blepharitis,” said Justin Hall, NovaBay CEO. “NovaWipes are also
hypoallergenic, allowing patients to feel safe with their routine
use. Their multi-layer construction provides maximum absorption,
and their woven structure means they won’t pull apart like ordinary
cotton rounds or balls. They are also larger than the average
cotton round, providing more surface area for dabbing and
blotting.
“NovaWipes represent the second of several Avenova Direct line
extensions and complementary products we are introducing to drive
cost-effective growth and leverage our distribution
infrastructure,” said Hall. “Last month we launched NovaSight™, a
proprietary vitamin and mineral supplement specially designed to
support ocular health.”
“As an optometric clinician who specializes in ocular surface
disease, I am gratified to see the next evolutionary logical step
with the development and commercialization of NovaWipes,” said Dr.
Michael S. Cooper of Solinsky EyeCare in West Hartford, Conn. and
President of Intrepid Eye Society. “Harnessing the power of
hypochlorous acid in a neutralized formula in conjunction with this
hypoallergenic wipe makes it more appealing and approachable to
patients, especially those who wear makeup. In our ever
increasingly busy lives, this solution can assist those in need
with meibomian gland dysfunction and in extension dry eye
management in a cost effective manner.”
NovaWipes are available on Amazon.com in the U.S. in a 30-count
package for $5.99.
About NovaBay Pharmaceuticals, Inc.: Going Beyond
Antibiotics®
NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company
focusing on commercializing and developing its non-antibiotic
anti-infective products to address the unmet therapeutic needs of
the global, topical anti-infective market with its two distinct
product categories: the NEUTROX® family of products and the
AGANOCIDE® compounds. The Neutrox family of products includes
AVENOVA® for the eye care market, NEUTROPHASE® for wound care
market, and CELLERX® for the aesthetic dermatology market. The
Aganocide compounds, still under development, have target
applications in the dermatology and urology markets.
Forward-Looking Statements
This release contains forward-looking statements that are based
upon management’s current expectations, assumptions, estimates,
projections and beliefs. These statements include, but are not
limited to, statements regarding our business strategies and future
focus, the launch of a new product and the impact it may have on
our future financial results. These statements involve known and
unknown risks, uncertainties and other factors that may cause
actual results or achievements to be materially different and
adverse from those expressed in or implied by the forward-looking
statements. Factors that might cause or contribute to such
differences include, but are not limited to, risks and
uncertainties relating to the size of the potential market for our
products, potential uses of our product, market acceptance, and any
potential regulatory problems. Other risks relating to NovaBay’s
business, including risks that could cause results to differ
materially from those projected in the forward-looking statements
in this press release, are detailed in NovaBay’s latest Form 10-Q/K
filings with the Securities and Exchange Commission, especially
under the heading “Risk Factors.” The forward-looking statements in
this release speak only as of this date, and NovaBay disclaims any
intent or obligation to revise or update publicly any
forward-looking statement except as required by law.
Socialize and Stay informed on
NovaBay’s progress Like us on Facebook Follow
us on Twitter Connect with NovaBay on LinkedIn Visit
NovaBay’s Website
View source
version on businesswire.com: https://www.businesswire.com/news/home/20191202005100/en/
NovaBay Contact Justin Hall
President and Chief Executive Officer 510-899-8800
jhall@novabay.com
Investor Contact LHA
Investor Relations Jody Cain 310-691-7100 jcain@lhai.com
NovaBay Pharmaceuticals (AMEX:NBY)
Historical Stock Chart
From Aug 2024 to Sep 2024
NovaBay Pharmaceuticals (AMEX:NBY)
Historical Stock Chart
From Sep 2023 to Sep 2024